has made a second acquisition in two months in the active pharmaceutical ingredients (API) segment. The company’s wholly-owned subsidiary, RPG Active Pharma Ltd (RPGAP) has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences Private Ltd on a going-concern basis through a slump sale, for a consideration of up to ₹135 crore, it said.
Last month, RPGLS agreed to transfer its API business to RPG Active Pharma Ltd, even as it has announced plans to acquire Actis Generics Private Ltd – a Visakhapatnam-based API manufacturing company.
The latest acquisition is the next step in RPGAP’s consolidation based on a buy-and-build strategy to bolster growth and create an integrated, scaled API focused organisation, it said. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP’s manufacturing base, product portfolio, regulatory capabilities and customer access across geographies, it added. The acquisition will be funded in line with the recent equity raise announced by RPGAP.
Raghava operates a modern API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated research set-up, RPG said.
“The facility is WHO-GMP and EU-GMP approved with significant investment towards capacity expansion in recent years. Its established regulatory approvals, meaningful installed capacity and chemistry capabilities provide RPGAP with a high-quality manufacturing presence,” it added.
The business has developed a portfolio of high-growth APIs, comprising 22 commercialised products and seven development-stage assets across diabetes, cardiovascular, CNS and other therapeutic segments. The portfolio includes commercially attractive molecules and has multiple international regulatory credentials, besides a broad basket of commercialised and pipeline APIs, it added. The acquisition will be funded in line with the recent equity raise announced by RPGAP.
The transaction includes business with revenues of about Rs 19 crore in FY26 (unaudited), along with manufacturing facilities, R&D facility and a portfolio of 29 API molecules, of which 22 are commercialised and 7 are under development. “No shares are being purchased in any entity and no entity is being acquired,” the company told the .
Ashok Nair, Managing Director, RPG Life Sciences Ltd, said, “This acquisition marks an important addition to the RPG Active Pharma Ltd consolidated organisation. It brings together a high-quality manufacturing asset, a broad portfolio of commercialised APIs, established regulatory credentials and strong customer relationships. Following Actis, it further strengthens the scale and capabilities of RPGAP and advances our strategy of building an integrated and competitive scaled API business. The real opportunity lies in unlocking the potential of the asset through stronger commercialisation, improved capacity utilisation and integration across the organisation. By combining these manufacturing and product capabilities with Actis’ intermediate strengths and RPGAP’s governance, talent and market access, we intend to build a larger presence and capture a greater share of the growing API market.”
Lohith Ponguleti, Managing Director, Raghava Life Sciences Private Ltd, added, “Over the years, we have built a differentiated business anchored by an EU-GMP approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential.”
Quillan Partners acted as the legal advisors, o3 Capital acted as the financial advisors and Deloitte acted as the Financial Due Diligence partner to RPG Active Pharma Ltd, the note said.